Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | glucagon-like peptide 1 receptor | Starlite/ChEMBL | No references |
Homo sapiens | lamin A/C | Starlite/ChEMBL | No references |
Homo sapiens | glycoprotein hormones, alpha polypeptide | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Toxoplasma gondii | intraflagellar transport protein 172, putative | glycoprotein hormones, alpha polypeptide | 116 aa | 94 aa | 26.6 % |
Loa Loa (eye worm) | pigment dispersing factor receptor c | glucagon-like peptide 1 receptor | 463 aa | 388 aa | 25.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | latrophilin receptor protein 2 | 0.0019 | 0.0375 | 0.0375 |
Onchocerca volvulus | 0.0033 | 0.3537 | 0.5 | |
Loa Loa (eye worm) | hypothetical protein | 0.0041 | 0.5545 | 0.5545 |
Brugia malayi | intermediate filament protein | 0.0033 | 0.3537 | 0.3537 |
Loa Loa (eye worm) | intermediate filament protein | 0.0033 | 0.3537 | 0.3537 |
Schistosoma mansoni | lamin | 0.0033 | 0.3537 | 0.6116 |
Loa Loa (eye worm) | hypothetical protein | 0.0019 | 0.0375 | 0.0375 |
Echinococcus granulosus | lamin | 0.0033 | 0.3537 | 1 |
Echinococcus granulosus | lamin dm0 | 0.0033 | 0.3537 | 1 |
Brugia malayi | calcium-independent alpha-latrotoxin receptor 2, putative | 0.0019 | 0.0375 | 0.0375 |
Schistosoma mansoni | intermediate filament proteins | 0.0033 | 0.3537 | 0.6116 |
Onchocerca volvulus | 0.0033 | 0.3537 | 0.5 | |
Loa Loa (eye worm) | intermediate filament tail domain-containing protein | 0.0033 | 0.3537 | 0.3537 |
Schistosoma mansoni | lamin | 0.0033 | 0.3537 | 0.6116 |
Echinococcus multilocularis | musashi | 0.0033 | 0.3537 | 1 |
Echinococcus multilocularis | lamin | 0.0033 | 0.3537 | 1 |
Brugia malayi | Latrophilin receptor protein 2 | 0.0019 | 0.0375 | 0.0375 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.006 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0032 | 0.3397 | 0.3397 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.006 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.006 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0033 | 0.3537 | 0.3537 |
Schistosoma mansoni | hypothetical protein | 0.0041 | 0.5545 | 1 |
Echinococcus multilocularis | lamin dm0 | 0.0033 | 0.3537 | 1 |
Brugia malayi | Intermediate filament tail domain containing protein | 0.0033 | 0.3537 | 0.3537 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0041 | 0.5545 | 0.5545 |
Echinococcus granulosus | intermediate filament protein | 0.0033 | 0.3537 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 5.6234 uM | PubChem BioAssay. qHTS for Activators of Integrin-Mediated Alleviation for Muscular Dystrophy. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 8.9125 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 14.1254 um | PUBCHEM_BIOASSAY: qHTS Assay for Modulators of Lamin A Splicing. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 29.0929 uM | PUBCHEM_BIOASSAY: qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493107, AID493125] | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.